Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 64, Issue 10, 2012, Pages 3364-3373

  Merrill, Joan T ^a   Ginzler, Ellen M ^b   Wallace, Daniel J ^c   McKay, James D ^d   Lisse, Jeffrey R ^e   Aranow, Cynthia ^f   Wellborne, Frank R ^g   Burnette, Michael ^h   Condemi, John ⁱ   Zhong, Z John ^j   Pineda, Lilia ^j   Klein, Jerry ^j   Freimuth, William W ^j  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Oklahoma Center for Arthritis Therapy and Research   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^g Houston Institute for Clinical Research   (United States)

^h Tampa Medical Group   (United States)

ⁱ UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^j GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BELIMUMAB; CORTICOSTEROID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO;

ABDOMINAL PAIN; ADULT; ANGIONEUROTIC EDEMA; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; BRONCHITIS; CELLULITIS; CHEST TIGHTNESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPERSENSITIVITY; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LUNG CANCER; LYMPHOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAUSEA; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; PATIENT SATISFACTION; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUSITIS; SQUAMOUS CELL CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO; VOMITING;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84869072981     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34564     Document Type: Article

References (33)

1. Manson JJ, Rahman A. Systemic lupus erythematosus. Orphanet J Rare Dis 2006;1:6.
2. Pisetsky DS. Systemic lupus erythematosus: epidemiology, pathology, and pathogenesis. In: Klippel JH, Crofford LJ, Stone JH, Weyand CM, editors. Primer on the rheumatic diseases. 12th ed. Atlanta: Arthritis Foundation; 2001. p. 329-35.
3. Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001; 10: 140-7. (Pubitemid 32410067)
4. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-8. (Pubitemid 30642567)
5. Bernatsky S, Joseph L, Boivin JF, Gordon C, Urowitz M, Gladman D, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008; 67: 74-9.
6. Karim MY, Alba P, Cuadrado MJ, Abbs IC, D'Cruz DP, Khamashta MA, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002; 41: 876-82.
7. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, the European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82:299-308. (Pubitemid 37229465)
8. Goldblatt F, Chambers S, Rahman A, Isenberg DA. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 2009; 18: 682-9.
9. Campbell R Jr, Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. Arthritis Rheum 2008; 59: 458-64. (Pubitemid 351563526)
10. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantovet R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406. (Pubitemid 37542988)
11. Urowitz MB, Gladman D, Ibanez D, Fortin P, Sanchez-Guerrero J, Bae S, et al, and the Systemic Lupus International Collaborating Clinics. Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum 2008; 59: 176-80. (Pubitemid 351272951)
12. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1481-90. (Pubitemid 40663940)
13. Bernatsky S, Ramsey-Goldman R, Isenberg D, Rahman A, Dooley MA, Sibley J, et al. Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46: 830-2. (Pubitemid 47061717)
14. Parikh-Patel A, White RH, Allen M, Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 2008; 19: 887-94.
15. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus: results from a single center. I. Causes of death. J Rheumatol 1995; 22: 1259-64.
16. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-7. (Pubitemid 44205016)
17. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3. (Pubitemid 29330000)
18. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48: 3253-65. (Pubitemid 37409340)
19. Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006; 91: 586-99. (Pubitemid 43827311)
20. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune- based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-9. (Pubitemid 32537529)
21. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453-9.
22. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10. (Pubitemid 32038409)
23. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1168-78.
24. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al, for the BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30.
25. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebocontrolled, phase 3 trial. Lancet 2011; 377: 721-31.
26. National Institute of Allergy and Infectious Diseases. Division of Microbiology and Infectious Diseases (DMID) Adult Toxicity Tables. 2007. URL: http://www.niaid.nih.gov/labsandresources/ resources/dmidclinrsrch/pages/ toxtables.aspx.
27. Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol 2008;26 Suppl 51:S72-9.
28. Karim MY, Pisoni CN, Khamashta MA. Update on immunotherapy for systemic lupus erythematosus - what's hot and what's not! Rheumatology (Oxford) 2009; 48: 332-41.
29. Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2010; 22: 504-9.
30. Appel GB, Contreras G, Dooley DA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-12.
31. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA, for the ALMS Group. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010; 62: 211-21.
32. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-28. (Pubitemid 41697285)
33. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus 2010; 19: 703-10.